- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00275262
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Leuprolide Acetate to Enhance Immune Function Post-Autologous Stem Cell Transplantation
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
-
-
New York
-
New York, New York, United States, 10021
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
-
-
Texas
-
Houston, Texas, United States, 77030
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be female between the ages of 18 - 50 or if female > 50 years old have an estradiol concentration level >= 30 pg/mL and follicle stimulating hormone level < 40 mIU/mL, or male between the ages of 18-65 (inclusive).
Must have Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma and be considered an appropriate candidate for hematopoietic stem cell transplant.
- Multiple myeloma patients should have had a partial or complete response to chemotherapy.
- Patients with Hodgkin's disease or non-Hodgkin's lymphoma who achieve a partial response to initial chemotherapy or first or second chemosensitive relapse, achieving a complete or partial response to salvage treatment. Patients in first remission with mantle cell lymphoma, or with intermediate or high grade lymphoma, presenting with high intermediate or high IPI (International Prognostic Index) scores are also eligible.
- Must be seronegative for hepatitis C and HIV.
- Must have received prior tetanus immunization
- Must not have received prior KLH immunization.
- Must have an ECOG performance status (PS) <= 1 or Karnofsky PS >= 70%.
- Must have creatinine <= 2.0 mg/dL; ejection fraction > 45%; carbon monoxide diffusion in the lungs (DLCO) > 50% of predicted; serum bilirubin < 1.5 times the upper limit of normal unless Gilbert's syndrome, SGPT < 3 times normal value.
- Must be more than 3 weeks from any prior surgery (except for central line placement) and have fully recovered from the effects of surgery.
- Must have an absolute neutrophil count (ANC) >= 1,500 µL, platelet count >= 100,000/µL and hemoglobin >= 8.0 gm/dL within 21 days prior to randomization.
- Must be able to return to the clinical site for follow-up visits.
- Must be able to provide written consent.
Exclusion Criteria:
- Must not have an uncontrolled life-threatening infection (or active infectious process requiring intravenous [IV] systemic medical therapy within 1 week prior to study enrollment).
- Must not have a diagnosed or suspected schistosomiasis infection.
- Must not have previously received hematopoietic stem cell transplantation.
- Must not require a tandem transplant.
- Must not be female with a positive pregnancy test, pregnant, or lactating and breast feeding, or wish to become pregnant during the course of the study. Must agree to use barrier method of contraception.
- Must not be receiving estrogen or testosterone replacement therapy,phytoestrogen, phyto-testosterone, or oral contraceptives (patients may enroll if oral contraceptives are ceased prior to study entry), or have been administered Depo Provera within 3 months of entering the study.
- Must not have had prior mediastinal or sternal radiation.
- Must not have received any investigational drug other than antibiotics within 3 weeks prior to study drug administration or are scheduled to receive an investigational drug during the course of this study.
- Must not have unstable cardiac arrhythmias, uncontrolled congestive heart failure, history of myocardial infarction (MI) or ischemia, stroke, or embolic events within 6 months before study start.
- Must not have medical or psychiatric conditions that, in the opinion of the investigator, would compromise the patient's ability to participate in the study.
- Must not be receiving or plan to receive palifermin (KGF).
- Must not have a allergy to shellfish.
- Must not have previously taken a GnRH analog within 18 months.
- Must not be a woman who has undergone bilateral oophorectomy, or man with orchiectomy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LAD 11.25 mg 3 Month Depot
Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
|
LAD intramuscular injection 11.25 mg, 3 month duration.
To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Other Names:
|
PLACEBO_COMPARATOR: Placebo Comparator
Three intramuscular injections of matched placebo administered approximately 3 months apart.
|
Matched placebo intramuscular injection, 3 month duration.
To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in IgM Response (Mcg/mL) Before Keyhole Limpet Hemocyanin (KLH) Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
Time Frame: Month 6 prevaccination (baseline) and Month 7 postvaccination
|
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo.
Serum immunoglobulin IgM antibodies were determined by enzyme-linked immunosorbent assay (ELISA).
Baseline is defined as the IgM concentration before the KLH vaccination.
Change from baseline was calculated as the IgM value postvaccination minus the IgM value at prevaccination.
|
Month 6 prevaccination (baseline) and Month 7 postvaccination
|
Mean Change From Baseline in IgG1 Response (Mcg/mL) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
Time Frame: Month 6 prevaccination (baseline) and Month 7 postvaccination
|
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo.
Serum immunoglobulin IgG1 antibodies were determined by enzyme-linked immunosorbent assay (ELISA).
Baseline is defined as the IgG1 concentration before the KLH vaccination.
Change from baseline was calculated as the IgG1 value postvaccination minus the IgG1 value at baseline.
|
Month 6 prevaccination (baseline) and Month 7 postvaccination
|
Mean Change From Baseline in Interferon Gamma Response (Spots/1 Million Cells) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo
Time Frame: Month 6 prevaccination (baseline) and Month 7 postvaccination
|
Patients received a subcutaneous injection of KLH vaccine 1 month after subjects received the third injection of LAD or placebo.
Interferon gamma was determined by enzyme-linked immunosorbent spot-forming cell (ELISpot).
Baseline is defined as the interferon gamma concentration obtained before the KLH vaccination.
Change from baseline was calculated as the interferon gamma value postvaccination minus the interferon gamma value at baseline.
|
Month 6 prevaccination (baseline) and Month 7 postvaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in T Cell Excision Circles (TREC) Per 100,000 CD4+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
Time Frame: Pretransplant and posttransplant (Month 12)
|
CD4+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD4 cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD4+ cells minus pretransplant TREC /100,000 CD4+ cells. |
Pretransplant and posttransplant (Month 12)
|
Mean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
Time Frame: Pretransplant and posttransplant (Month 12)
|
CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells. |
Pretransplant and posttransplant (Month 12)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Lymphoma
- Multiple Myeloma
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Leuprolide
Other Study ID Numbers
- L-BT04-093
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Acerta Pharma BVAstraZenecaActive, not recruitingNon Hodgkin LymphomaUnited States, Canada, Italy
Clinical Trials on Leuprolide acetate depot (LAD) 11.25 mg 3 Month
-
AbbottFraktal.com.pl; Med-net.plCompletedLower Urinary Tract Symptoms | Advanced Prostate CancerPoland, Ukraine
-
AbbottCompletedPuberty, PrecociousUnited States, Puerto Rico
-
AbbVie (prior sponsor, Abbott)CompletedCentral Precocious Puberty (CPP) | Precocious | Leuprolide Acetate | Luteinizing Hormone (LH) | Gonadotrophin-releasing Hormone Agonist (GnRHa) | Tanner Staging | Depot Formulation | Suppression of LH | Gonadotrophin-releasing Hormone (GnRH) | Lupron | GnRH Analog | Pediatrics Central Precocious PubertyUnited States, Puerto Rico
-
Centre for Endocrinology and Reproductive Medicine...Completed
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
National Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7United States
-
Daewoong Pharmaceutical Co. LTD.Recruiting
-
Dana-Farber Cancer InstituteMedivation, Inc.CompletedProstate Cancer | Prostate Adenocarcinoma | High Risk Prostate CancerUnited States
-
Joseph MccuneEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedLupus Erythematosus, Systemic | Systemic Vasculitis | Lung Disease With Systemic Sclerosis | Isolated Angiitis of Central Nervous System | Lung Disease Interstitial DiffuseUnited States
-
Repros Therapeutics Inc.TerminatedUterine FibroidsUnited States, Mexico